Q2 EPS Forecast for Core Laboratories Raised by Analyst

Core Laboratories Inc. (NYSE:CLB - Free Report) - Research analysts at Zacks Research lifted their Q2 2027 earnings per share estimates for Core Laboratories in a report issued on Tuesday, July 8th. Zacks Research analyst R. Department now expects that the oil and gas company will earn $0.26 per share for the quarter, up from their prior forecast of $0.25. The consensus estimate for Core Laboratories' current full-year earnings is $0.96 per share.

Core Laboratories (NYSE:CLB - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The firm had revenue of $123.59 million during the quarter, compared to analysts' expectations of $125.09 million. Core Laboratories had a net margin of 5.41% and a return on equity of 15.06%. The business's quarterly revenue was down 4.7% on a year-over-year basis. During the same quarter last year, the business earned $0.19 earnings per share.

Several other research firms have also commented on CLB. Stifel Nicolaus decreased their price objective on shares of Core Laboratories from $19.00 to $15.00 and set a "hold" rating on the stock in a research report on Tuesday, April 15th. Wall Street Zen downgraded shares of Core Laboratories from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Finally, Citigroup lowered their target price on shares of Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. According to data from MarketBeat.com, Core Laboratories has an average rating of "Hold" and an average price target of $15.00.

Core Laboratories Price Performance

Shares of NYSE CLB traded down $0.41 during trading on Friday, hitting $12.45. 230,637 shares of the company were exchanged, compared to its average volume of 449,954. The company has a market cap of $583.79 million, a price-to-earnings ratio of 21.11, a PEG ratio of 3.96 and a beta of 1.41. Core Laboratories has a 1 year low of $10.14 and a 1 year high of $25.13. The firm's fifty day moving average price is $11.82 and its 200 day moving average price is $14.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.21 and a quick ratio of 1.64.

Core Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, May 27th. Stockholders of record on Monday, May 5th were issued a dividend of $0.01 per share. The ex-dividend date was Monday, May 5th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.32%. Core Laboratories's payout ratio is 6.78%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Millennium Management LLC grew its stake in Core Laboratories by 429.0% in the fourth quarter. Millennium Management LLC now owns 65,616 shares of the oil and gas company's stock worth $1,136,000 after purchasing an additional 53,213 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Core Laboratories in the fourth quarter worth $464,000. Oppenheimer Asset Management Inc. lifted its stake in Core Laboratories by 19.8% in the first quarter. Oppenheimer Asset Management Inc. now owns 69,184 shares of the oil and gas company's stock valued at $1,037,000 after buying an additional 11,438 shares during the last quarter. Amundi increased its stake in shares of Core Laboratories by 194.8% in the fourth quarter. Amundi now owns 32,968 shares of the oil and gas company's stock valued at $600,000 after purchasing an additional 21,783 shares during the period. Finally, Northern Trust Corp increased its stake in Core Laboratories by 15.6% during the 4th quarter. Northern Trust Corp now owns 577,752 shares of the oil and gas company's stock valued at $10,001,000 after buying an additional 78,173 shares during the period. 97.81% of the stock is owned by hedge funds and other institutional investors.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.